Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating head and neck cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic) among rural Midwest patients. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid and may kill tumor cells. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving the combination of methotrexate, erlotinib, and celecoxib may be feasible, safe, and effective in treating rural Midwest patients with recurrent/metastatic head and neck cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej.
- •Potwierdzony rak głowy i szyi (w tym jama ustna, gardło, krtani), który powrócił lub się rozprzestrzenił.
- •Możliwość poddania się leczeniu lub odmowa terapii pierwszego rzutu.
- •Ogólny stan zdrowia pozwalający na udział w badaniu (oceniany według skali ECOG 0-2).
- •Odpowiednie wyniki badań krwi (hemoglobina, liczba neutrofilów, płytki krwi) wykonane do 15 dni przed badaniem.
- •Prawidłowe wyniki badań wątroby (bilirubina, ALT, AST) wykonane do 15 dni przed badaniem.
- •Prawidłowe wyniki krzepnięcia krwi (INR, aPTT) wykonane do 15 dni przed badaniem.
- •Odpowiednia czynność nerek (klirens kreatyniny) wykonana do 15 dni przed badaniem.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Mayo Clinic in Rochester
Rochester, United States
Trial contact
Clinical Trials Referral Office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.